Skip to main content

Table 4 Outcomes of 14 patients with AE-ILD after chemotherapy

From: Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

  No. Treatment line Associated regimens Onset of AE (days from chemotherapy) Outcome Survival time (days from onset of AE)
Non-Bev group 1 First CDDP + PEM 79 Recover 125
2 First CBDCA + PEM 110 Dead 87
3 First CBDCA + PEM 5 Recovered 125
4 First CBDCA + PEM 59 Dead 77
5 First CBDCA + PEM 45 Dead 11
6 First CBDCA + PEM 54 Recovered 626
7 First CBDCA + PTX 87 Dead 36
8 Second DOC 169 Recovered 276
9 Second DOC 193 Recovered 522
10 Second S-1 120 Dead 5
11 Second DOC 426 Dead 4
12 Third DOC 372 Dead 67
Bev group 13 Second nab-PTX 156 Dead 34
14 Third DOC 386 Dead 17
  1. AE acute exacerbation, Bev bevacizumab, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel, DOC docetaxel, nab-PTX nab-paclitaxel, VNR vinorelbine